Gilead Sciences

News

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

News

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.

News

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.